



## NEONATAL MEDICATION PROTOCOLS

**PHYTOMENADIONE (VITAMIN K)**  
Created by: NCCU  
Date for review: Oct 2016

NCCU Clinical Guidelines  
KEMH/PMH  
Perth, Western Australia

<b>DRUG:</b>	<b>PHYTOMENADIONE (VITAMIN K)</b>
<b>PRESENTATION:</b>	Ampoule: 2mg/0.2mL (for oral, IV, IM administration)
<b>ACTION &amp; INDICATION:</b>	Prevents haemorrhagic disease of the newborn by promoting the synthesis of blood coagulation factors in the liver.  For neonatal biliary atresia and liver disease
<b>DOSE:</b>	<b>Prophylaxis:</b> IM, IV, UA, UV: ≤ 1500g      0.5mg (0.05mL) as a single dose > 1500g      1mg (0.1mL) as a single dose  Oral: 3 doses to be administered Day 1: 2 mg (0.2mL) Day 2: If first dose not retained, repeat dose. Day 3 - 5: 2 mg (0.2mL) <b>Week 4 :</b> 2 mg.(0.2mL)  <b>Neonatal biliary atresia and liver disease:</b>  1mg daily
<b>PREPARATION:</b>	IV: May be diluted to 0.5mL if required for ease of administration  Diluent : Glucose 5, 10%, Glucose / saline, Sodium chloride 0.9%
<b>ADMINISTRATION:</b>	Intramuscular: As per NCCU policy. This is the preferred route of administration.  IV : Give slowly over 5-10 minutes  Umbilical arterial or venous injection  Oral: Contents of ampoule may be given orally.
<b>ADVERSE EFFECTS :</b>	Flushing, anaphylactic reaction, cyanosis, bronchospasm, rapid weak pulse, hypotension.  Excessive doses: hyperbilirubinaemia and kernicterus.
<b>REFERENCES:</b>	Paediatric Pharmacopoeia 13 <sup>th</sup> Ed Royal Children's Hospital Melbourne  BNF for Children 2013
<b>DATE:</b>	October 2013